BioMarin Pharmaceutical | BMRN - Себестоимость





Себестоимость Изменить Дата
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
Amgen USD 1.79B 128M 2025-12
Bayer EUR 4.5B 194M 2025-12
Biogen USD 797.5M 302M 2026-03
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Insmed USD 46.16M 15.25M 2025-12
Ionis Pharmaceuticals USD 3M 5M 2026-03
Moderna USD 452M 245M 2025-12
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 669.4M 84.8M 2026-03
Roche Holding CHF 8.48B 4.61B 2025-12
Sangamo BioSciences 2.42M 1.11M 2024-06
Sanofi EUR 3.76B 344M 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
United Therapeutics USD 474.7M 373.8M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12